Entries by George Lundberg, MD

Precision Medicine in the Universal Healthcare System in the Netherlands

Jack A. Schalken, PhD, Professor of Experimental Urology, Radboud University Medical Center, Nijmegen, NL Email: Jack.Schalken@radboudumc.nl Q: Science is universal but the practice of medicine varies widely by geography, economics, and culture. The Netherlands is an advanced developed country with universal healthcare. How does your country approach the issue of precision or molecular oncology? A: The […]

The Role of “Rapid Science” in Facilitating and Rewarding Collaboration in Biomedical Research

Sarah Greene, MS, Chief Executive Officer, Rapid Science, Brooklyn, NY; Email sg@rapidscience.org Q: You are the leader of Rapid Science, an innovative initiative intended to speed up the process of research and validation of new information, and its use in practice, especially in Cancer. Can you explain this effort briefly for our readers, particularly that […]

Q&A: Air Traffic Control for Cancer

Q: After May 17, 2017, you and Jeff Shrager engaged in a robust discussion about the place, if any, for an “Air Traffic Control system” called “Global Cumulative Treatment Analysis” (GCTA) for Cancer. Will you share excerpts with our readers? DC: I see some major ethical and financial problems with GCTA: Who is going to authorize and […]

Options to Treat a Glioblastoma

Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY; Email: musella@virtualtrials.com Phone: 888-295-4740 Q: You direct an established foundation that supports research and information about brain tumors. What would you do if you yourself were diagnosed with a glioblastoma multiforme (GBM)? A: Now that GBMs are in the news […]

Lung Cancer Screening…The Clock is Ticking

Paul R Billings MD, PhD, CEO and Chairman of Synergenz LTD Q: Lung cancer screening of smokers (spiral CT over 3 years) is paid for by CMS (reimbursement), has a B endorsement from USPTF (method endorsement), and lots of NEJM papers (academic evidence). As many as 8M eligibles noted since 2012. No more than 400K […]

How to Initiate Treatment for Chronic Myelogenous Leukemia March 2016 vs July 2017

Jerald P. Radich, MD, Director of the Molecular Oncology Lab at the Fred Hutchinson Cancer Research Center, and Professor of Medicine at the University of Washington School of Medicine Q: In March 2016, we published your blog about how to initiate therapy for an adult patient newly diagnosed with chronic myeloid leukemia (CML). As of July 2017, […]

How to Treat Metastatic Colorectal Cancer

Bassel El-Rayes, MD, Professor and Vice Chair for Clinical Research, Department of Hematology and Medical Oncology, Associate Director for Clinical Research, and Director of the Gastrointestinal Oncology Program Winship Cancer Institute of Emory University Q: You have just received a new patient, referred to you from Macon, GA. She is a 52-year-old white woman in good […]

You, Me, and 23: DTC Gene Tests

Melinda Roberts, Web and Product Development Lead Globiana Inc. Q: Many people are interested in their own genes and wonder whether they are predisposed to cancer or other maladies.  You recently participated in the “23 and me” testing process. As a well-educated and informed consumer, did you find that service useful? Were the explanations given sufficient? […]

Leading Retractions in the Cancer Research Literature

Q: You founded “Retraction Watch” in 2010. It has flourished and filled a substantial niche. In your view, what are the most important retractions or corrections in the cancer literature to date? A: Without passing judgment on the integrity of cancer research broadly speaking, we have indeed seen several significant cases involving retractions in this field. Topping the […]